Please assess the completion status of the following clinical trial:

Trial Title: Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD20 positive diffuse large B-cell lymphoma with bulky stage II or stage III or stage IV~* Bidimensionally measurable disease~* Performance status Zubrod 0-2~* Less than 20,000/mcL circulating lymphoid cells on WBC differential count~* No clinical evidence of CNS involvement, no prior diagnosis of indolent lymphoma, no histologic transformation~* Ejection fraction more than or equal to 45% by MUGA or no significant abnormality by echocardiogram~* Fertile patients with effective contraception method~* No other malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer, stage I or II cancer in complete remission, or carcinoma in situ of cervix~* No HIV positive, no prior solid organ transplantation~* No prior antibody therapy, chemotherapy, radiotherapy for lymphoma~Exclusion Criteria:~* Serum creatinine ot bilirubin more than 2.5 X ULN unless due to lymphoma~* Active uncontrolled infection~* Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study~* Patients with more than 25% infiltrated bone marrow~* Patients with platelet counts less than 100,000/mcL or neutrophil counts less than 1,500/mcL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).